BR112022007615A2 - Método para tratar ou prevenir papilomatose respiratória recorrente, e, sequência de nucleotídeo - Google Patents

Método para tratar ou prevenir papilomatose respiratória recorrente, e, sequência de nucleotídeo

Info

Publication number
BR112022007615A2
BR112022007615A2 BR112022007615A BR112022007615A BR112022007615A2 BR 112022007615 A2 BR112022007615 A2 BR 112022007615A2 BR 112022007615 A BR112022007615 A BR 112022007615A BR 112022007615 A BR112022007615 A BR 112022007615A BR 112022007615 A2 BR112022007615 A2 BR 112022007615A2
Authority
BR
Brazil
Prior art keywords
treat
nucleotide sequence
recurrent respiratory
disclosed
respiratory papillomatosis
Prior art date
Application number
BR112022007615A
Other languages
English (en)
Inventor
B Weiner David
Yan Jian
Original Assignee
Univ Pennsylvania
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Inovio Pharmaceuticals Inc filed Critical Univ Pennsylvania
Publication of BR112022007615A2 publication Critical patent/BR112022007615A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MÉTODO PARA TRATAR OU PREVENIR PAPILOMATOSE RESPIRATÓRIA RECORRENTE, E, SEQUÊNCIA DE NUCLEOTÍDEO. O uso de imunógenos anti-HPV e uma molécula de ácido nucleico que codifica os mesmos para o tratamento e a prevenção de RRP é divulgado. Composição farmacêutica, vacinas recombinantes compreendendo plasmídeo de DNA e vacinas atenuadas vivas são divulgadas, assim como métodos para induzir uma resposta imune para tratar ou prevenir RRP são divulgados.
BR112022007615A 2019-10-24 2020-10-26 Método para tratar ou prevenir papilomatose respiratória recorrente, e, sequência de nucleotídeo BR112022007615A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962925283P 2019-10-24 2019-10-24
PCT/US2020/057314 WO2021081480A2 (en) 2019-10-24 2020-10-26 Improved vaccines for recurrent respiratory papillomatosis and methods for using the same

Publications (1)

Publication Number Publication Date
BR112022007615A2 true BR112022007615A2 (pt) 2022-07-12

Family

ID=75620849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007615A BR112022007615A2 (pt) 2019-10-24 2020-10-26 Método para tratar ou prevenir papilomatose respiratória recorrente, e, sequência de nucleotídeo

Country Status (10)

Country Link
US (1) US20230000969A1 (pt)
EP (1) EP4048682A4 (pt)
JP (1) JP2022554132A (pt)
KR (1) KR20220114531A (pt)
CN (1) CN115443287A (pt)
AU (1) AU2020371792A1 (pt)
BR (1) BR112022007615A2 (pt)
CA (1) CA3155370A1 (pt)
MX (1) MX2022004836A (pt)
WO (1) WO2021081480A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240123052A1 (en) * 2022-10-13 2024-04-18 Inovio Pharmaceuticals, Inc. Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084364A2 (en) * 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Improved il-12 for expression in mammalian cells
KR20220035279A (ko) * 2011-10-12 2022-03-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법
CN102876684B (zh) * 2012-09-17 2014-10-08 青岛康立泰药业有限公司 人白细胞介素-12的编码基因、真核宿主细胞和表达方法
JP6517779B2 (ja) * 2013-03-12 2019-05-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスの改良型ワクチンおよびその使用方法

Also Published As

Publication number Publication date
WO2021081480A2 (en) 2021-04-29
MX2022004836A (es) 2022-07-19
US20230000969A1 (en) 2023-01-05
CA3155370A1 (en) 2021-04-29
EP4048682A2 (en) 2022-08-31
CN115443287A (zh) 2022-12-06
EP4048682A4 (en) 2023-11-01
WO2021081480A3 (en) 2021-06-03
KR20220114531A (ko) 2022-08-17
JP2022554132A (ja) 2022-12-28
AU2020371792A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
BR112014014078A8 (pt) Composições compreendendo constructos genéticos il-12 aperfeiçoados e vacinas, imunoterapêuticos e métodos de usar os mesmos
PH12018500855A1 (en) Herpes simplex virus vaccine
BR112019000015A2 (pt) distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
CO2018007203A2 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
BR112017005111A2 (pt) compostos, composição farmacêutica, usos de um composto ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de um hospedeiro infectado com um papilomavírus humano, usos de um composto, método para a fabricação de um medicamento destinado ao uso terapêutico para o tratamento de uma infecção por papilomavírus
CL2019000704A1 (es) Vectores de adenovirus canino.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
EA201990717A1 (ru) Новая вакцина против гриппа свиней
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
BR112018013503A2 (pt) bacteriófago recombinante, polinucleotídeo de genoma de bacteriófago recombinante, composição farmacêutica, vacina, e, método para tratamento de uma doença infecciosa.
CO2022017989A2 (es) Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas
BR112022007615A2 (pt) Método para tratar ou prevenir papilomatose respiratória recorrente, e, sequência de nucleotídeo
BR112021023899A2 (pt) Método para o tratamento da distrofia muscular por direcionamento ao gene da dmpk
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
WO2021202949A3 (en) Compositions and methods for treating vulvar dysplasia